Ranked #8,505 of 8,699 institutional investors
Ally Bridge Group (NY) LLC
New York, NY
$31.4M
US stock portfolio at live prices · today +$18K (+0.06%)
Market closed. Prices as of Nov 20, 9:11 AM ET
- Value at quarter end (Q3 2026)
- $43.4M
- Change from Q2 2026
- −$34.2M (−44.06%)
- Positions
- 14 · 4 new, 12 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $32.6M of stock.
Holdings
Q3 2026 13F, live pricesEWTX 24.3%AMLX 15.2%OBX 11.7%NERV 11.2%STTK 9.05%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| EWTX Edgewise Therapeutics, Inc. | 185,430 | $7.6M | 24.3% | Added +123% |
| AMLX Amylyx Pharmaceuticals, Inc. | 182,000 | $4.8M | 15.2% | New |
| OBX Obsidian Therapeutics, Inc. | 302,449 | $3.7M | 11.7% | New |
| NERV Minerva Neurosciences, Inc. | 1,655,500 | $3.5M | 11.2% | Reduced −24% |
| STTK Shattuck Labs, Inc. | 625,190 | $2.8M | 9.05% | New |
| ANTX AN2 Therapeutics, Inc. | 526,315 | $2.7M | 8.75% | Unchanged |
| PMN ProMIS Neurosciences, Inc. | 620,319 | $2.0M | 6.34% | Unchanged |
| EPRX Eupraxia Pharmaceuticals Inc. | 231,122 | $1.4M | 4.50% | Reduced −8% |
| AVTX Avalo Therapeutics, Inc. | 134,429 | $907K | 2.89% | Reduced −10% |
| IVA Inventiva S.A. | 227,250 | $784K | 2.50% | Reduced −64% |
| VOGX Vogenx, Inc. | 32,701 | $419K | 1.33% | New |
| ASMB Assembly Biosciences, Inc. | 18,298 | $412K | 1.31% | Reduced −87% |
| TRAW Traws Pharma, Inc. | 786,236 | $181K | 0.58% | Unchanged |
| CATX Perspective Therapeutics, Inc. | 163,634 | $128K | 0.41% | Reduced −78% |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| TRAX First Tracks Biotherapeutics, Inc. | 284,287 | $12.6M |
| WHWK Whitehawk Therapeutics, Inc. | 817,939 | $2.6M |
| CLYM Climb Bio Inc | 249,172 | $2.3M |
| AXSM Axsome Therapeutics, Inc. | 16,493 | $2.2M |
| KURA Kura Oncology, Inc. | 290,000 | $2.1M |
| IDYA IDEAYA Biosciences, Inc. | 67,500 | $1.8M |
| SLDB Solid Biosciences Inc. | 255,959 | $1.6M |
| CTMX CytomX Therapeutics, Inc. | 775,000 | $1.6M |
| OVID Ovid Therapeutics Inc. | 624,561 | $1.5M |
| PALI Palisade Bio, Inc. | 1,229,000 | $1.1M |
| ALMS Alumis Inc. | 76,459 | $331K |
| IBIO iBio, Inc. | 390,147 | $313K |